MA27798A1 - DERIVES DE BENZIMIDAZOLE COMME INHIBITEURS DU FACTEUR Xa - Google Patents
DERIVES DE BENZIMIDAZOLE COMME INHIBITEURS DU FACTEUR XaInfo
- Publication number
- MA27798A1 MA27798A1 MA28587A MA28587A MA27798A1 MA 27798 A1 MA27798 A1 MA 27798A1 MA 28587 A MA28587 A MA 28587A MA 28587 A MA28587 A MA 28587A MA 27798 A1 MA27798 A1 MA 27798A1
- Authority
- MA
- Morocco
- Prior art keywords
- factor
- compounds
- factor viia
- disorders
- formula
- Prior art date
Links
- 229940123583 Factor Xa inhibitor Drugs 0.000 title 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011305A EP1479676A1 (en) | 2003-05-19 | 2003-05-19 | Benzimidazole-derivatives as factor xa inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27798A1 true MA27798A1 (fr) | 2006-03-01 |
Family
ID=33040952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28587A MA27798A1 (fr) | 2003-05-19 | 2005-11-08 | DERIVES DE BENZIMIDAZOLE COMME INHIBITEURS DU FACTEUR Xa |
Country Status (29)
| Country | Link |
|---|---|
| EP (2) | EP1479676A1 (enExample) |
| JP (1) | JP4658940B2 (enExample) |
| KR (1) | KR20060014056A (enExample) |
| CN (2) | CN100484935C (enExample) |
| AR (1) | AR045683A1 (enExample) |
| AT (1) | ATE474838T1 (enExample) |
| AU (1) | AU2004238497B2 (enExample) |
| BR (1) | BRPI0410446A (enExample) |
| CA (1) | CA2526065A1 (enExample) |
| CL (1) | CL2004001078A1 (enExample) |
| CR (1) | CR8087A (enExample) |
| DE (1) | DE602004028240D1 (enExample) |
| EC (1) | ECSP056178A (enExample) |
| MA (1) | MA27798A1 (enExample) |
| MX (1) | MXPA05012231A (enExample) |
| NO (1) | NO20055910L (enExample) |
| NZ (1) | NZ543670A (enExample) |
| OA (1) | OA13168A (enExample) |
| PA (1) | PA8603501A1 (enExample) |
| PE (1) | PE20050198A1 (enExample) |
| RS (1) | RS20050856A (enExample) |
| RU (1) | RU2346944C2 (enExample) |
| SA (1) | SA04250196B1 (enExample) |
| TN (1) | TNSN05297A1 (enExample) |
| TW (1) | TW200503696A (enExample) |
| UA (1) | UA82100C2 (enExample) |
| UY (1) | UY28324A1 (enExample) |
| WO (1) | WO2004101553A1 (enExample) |
| ZA (1) | ZA200508151B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10342570A1 (de) * | 2003-09-15 | 2005-04-14 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon |
| US20060160799A1 (en) | 2004-04-23 | 2006-07-20 | Alekshun Michael N | Transcription factor modulating compounds and methods of use thereof |
| WO2008033739A2 (en) * | 2006-09-12 | 2008-03-20 | Neurogen Corporation | Benzimidazole carboxamide derivatives |
| DE102010018299A1 (de) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on |
| JP6535007B2 (ja) * | 2013-12-20 | 2019-06-26 | インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ | 新規ピペリジンカルボキサミド化合物、その調製方法及び使用 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2019223182B2 (en) | 2018-02-26 | 2021-08-19 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as HBV replication inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1377642A (en) * | 1971-01-14 | 1974-12-18 | Koninklijke Gist Spiritus | Penicillanic and cephalosporanic acid derivatives |
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
| US4897401A (en) * | 1987-06-19 | 1990-01-30 | Janssen Pharmaceutical N.V. | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases |
| DE3828537A1 (de) * | 1988-08-23 | 1990-03-01 | Basf Ag | Neue n-substituierte benzimidazol-2-carbonsaeureanilide, deren verwendung als lichtschutzmittel, insbesondere polymere und diese anilide enthaltendes organisches material |
| JPH0324609A (ja) * | 1989-06-21 | 1991-02-01 | Mitsuba Electric Mfg Co Ltd | Ｉ／ｏ用バッファｉｃ |
| JPH03184043A (ja) * | 1989-12-14 | 1991-08-12 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| KR100190299B1 (ko) * | 1990-07-19 | 1999-06-01 | 디르크 반테 | 신규한 옥사졸릴 유도체 |
| DE4304650A1 (de) * | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| CA2200959C (en) * | 1994-09-30 | 2000-05-23 | Kishor A. Desai | 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives |
| JPH08208640A (ja) * | 1995-02-06 | 1996-08-13 | Nisshin Flour Milling Co Ltd | ベンズイミダゾール誘導体およびそれを含有する心不全治療薬 |
| JPH08295667A (ja) * | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
| JPH09124609A (ja) * | 1995-11-07 | 1997-05-13 | Nissan Chem Ind Ltd | ベンズイミダゾール誘導体 |
| JPH10182459A (ja) * | 1996-12-26 | 1998-07-07 | Otsuka Pharmaceut Co Ltd | ｃＧＭＰ分解酵素阻害剤 |
| UA62972C2 (en) * | 1997-07-03 | 2004-01-15 | Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders | |
| DE69919149D1 (de) * | 1998-04-10 | 2004-09-09 | Japan Tobacco Inc | Amidin-verbindungen |
| BR0314059A (pt) * | 2002-09-06 | 2005-07-05 | Janssen Pharmaceutica Nv | Compostos heterocìclicos |
-
2003
- 2003-05-19 EP EP03011305A patent/EP1479676A1/en not_active Withdrawn
-
2004
- 2004-05-03 PE PE2004000446A patent/PE20050198A1/es not_active Application Discontinuation
- 2004-05-05 RS YUP-2005/0856A patent/RS20050856A/sr unknown
- 2004-05-05 OA OA1200500322A patent/OA13168A/en unknown
- 2004-05-05 CA CA002526065A patent/CA2526065A1/en not_active Abandoned
- 2004-05-05 DE DE602004028240T patent/DE602004028240D1/de not_active Expired - Lifetime
- 2004-05-05 NZ NZ543670A patent/NZ543670A/en unknown
- 2004-05-05 BR BRPI0410446-3A patent/BRPI0410446A/pt not_active IP Right Cessation
- 2004-05-05 KR KR1020057022122A patent/KR20060014056A/ko not_active Ceased
- 2004-05-05 MX MXPA05012231A patent/MXPA05012231A/es active IP Right Grant
- 2004-05-05 RU RU2005139555/04A patent/RU2346944C2/ru not_active IP Right Cessation
- 2004-05-05 AU AU2004238497A patent/AU2004238497B2/en not_active Expired - Fee Related
- 2004-05-05 JP JP2006529739A patent/JP4658940B2/ja not_active Expired - Fee Related
- 2004-05-05 CN CNB2004800139377A patent/CN100484935C/zh not_active Expired - Fee Related
- 2004-05-05 AT AT04731162T patent/ATE474838T1/de not_active IP Right Cessation
- 2004-05-05 CN CNA2007101491602A patent/CN101139346A/zh active Pending
- 2004-05-05 WO PCT/EP2004/004750 patent/WO2004101553A1/en not_active Ceased
- 2004-05-05 EP EP04731162A patent/EP1636216B1/en not_active Expired - Lifetime
- 2004-05-05 UA UAA200512138A patent/UA82100C2/uk unknown
- 2004-05-17 AR ARP040101695A patent/AR045683A1/es not_active Application Discontinuation
- 2004-05-17 CL CL200401078A patent/CL2004001078A1/es unknown
- 2004-05-17 TW TW093113795A patent/TW200503696A/zh unknown
- 2004-05-19 PA PA20048603501A patent/PA8603501A1/es unknown
- 2004-05-19 UY UY28324A patent/UY28324A1/es unknown
- 2004-06-30 SA SA04250196A patent/SA04250196B1/ar unknown
-
2005
- 2005-10-10 ZA ZA200508151A patent/ZA200508151B/xx unknown
- 2005-11-08 MA MA28587A patent/MA27798A1/fr unknown
- 2005-11-11 CR CR8087A patent/CR8087A/es not_active Application Discontinuation
- 2005-11-18 TN TNP2005000297A patent/TNSN05297A1/en unknown
- 2005-11-18 EC EC2005006178A patent/ECSP056178A/es unknown
- 2005-12-13 NO NO20055910A patent/NO20055910L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN04091A1 (en) | Indole-2-carboxamides as factor xa inhibitors | |
| CL2004001074A1 (es) | COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA, | |
| MA63501B1 (fr) | Dérivés d'urée pouvant être utilisés pour traiter le cancer | |
| CL2004001080A1 (es) | COMPUESTOS DERIVADOS DE INDAZOL, INHIBIDORES DEL FACTOR Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA Y OTRAS. | |
| TW200505914A (en) | Pyrazole-derivatives as factor Xa inhibitors | |
| BR0116473A (pt) | Derivados de oxibenzamidas como inibidores de fator xa | |
| MA26697A1 (fr) | Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant | |
| MA27647A1 (fr) | Antagonistes de ccr5 utiles comme agents therapeutiques | |
| MA29693B1 (fr) | Derives de xanthine en tant qu'agonistes hm74a selectifs | |
| MA31283B1 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
| TWI222865B (en) | Pharmaceutical composition for treatment of thromboembolic disorder or atherosclerosis or to inhibit blood coagulation | |
| CA2387857A1 (en) | Tissue factor antagonists and methods of use thereof | |
| MA27798A1 (fr) | DERIVES DE BENZIMIDAZOLE COMME INHIBITEURS DU FACTEUR Xa | |
| JP4841433B2 (ja) | 治療的処置 | |
| YU29702A (sh) | N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju | |
| MA27799A1 (fr) | DERIVES DE L'AZAINDOLE COMME INHIBITEURS DU FACTEUR Xa | |
| ATE394396T1 (de) | Triazolderivate als faktor-xa-inhibitoren | |
| Maekawa et al. | Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor | |
| TH65773A (th) | อนุพันธ์อินโดลชนิดใหม่ใช้เป็นสารยับยั้ง Xa แฟกเตอร์ | |
| JO2467B1 (en) | New indole derivatives as an inhibitor of Xa | |
| MA28302A1 (fr) | Derives de sulfonamides pour le traitement de maladies | |
| JP2011006391A (ja) | セトラキサートを含有する花粉症治療又は予防のための医療用組成物 |